Zentalis
123 employees on LinkedIn · 2 known investors
Zentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
Founders & leadership
JE
Julie EastlandinChief Executive Officer and Director
Board
SM
Scott MyersChairperson
Investors · 2
In the news
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | The Manila Timesmanilatimes.net · Aug 2026
Zentalis raises $92.6M for trials, filings and what followsstocktitan.net · Aug 2026
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering | The Manila Timesmanilatimes.net · Aug 2026
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering - August 13, 2026 - BioSpacebiospace.com · Aug 2026
Zentalis Sets $3.50 Share Price to Fund Clinical Trialsstocktitan.net · Aug 2026Frequently asked questions
- What does Zentalis do?
- Zentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
- Who are Zentalis's investors?
- Zentalis's investors include Decheng Capital, Highlight Capital.